Hepatocellular CarcinomaNCT05143619
Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines
An observational study of Hepatocellular Carcinoma, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
This study evaluates a concept called 'Teaching the Teachers' and whether it is helpful in disseminating guidelines on the national and international levels. "Teaching the Teachers" involves teaching the guidelines to experts who later teach the same guidelines to other radiologists, trainees, and physicians to assume… Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Hepatocellular Carcinoma
- What is being tested?
- Survey Administration
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 10 May 2019to 2 Feb 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Abdominal radiologists with expertise in liver imaging working in academic, community, and governmental practices in many centers around the world.
Who may be able to join
- Physicians who finished radiology residency
- Radiologists with current or completed specialized training in abdominal imaging
- Radiologists with expertise in liver imaging with no minimum number of years of experience
- Radiologists working in academic, community, and governmental practices
- Radiologists with current practice in any country around the globe
- Radiologists with and without previous knowledge of HCC diagnosis guidelines (Liver Imaging Reporting and Data System [LI-RADS])
- Radiologists with interest in education and/or teaching
Who cannot join
- Physicians with no formal training in radiology
- Radiologists with no expertise in abdominal/liver imaging
- Current radiology residents
- Radiologists with no interest in education and/or teaching
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
M D Anderson Cancer Center
Houston, Texas, 77030
Khaled M. Elsayes, MD, 713-794-1191, KMElysayes@mdanderson.org
Khaled M. Elsayes, MD
About this study
This study evaluates a concept called 'Teaching the Teachers' and whether it is helpful in disseminating guidelines on the national and international levels. "Teaching the Teachers" involves teaching the guidelines to experts who later teach the same guidelines to other radiologists, trainees, and physicians to assume the teacher's role and disseminate the guidelines and so on.
Read the detailed description
PRIMARY OBJECTIVES:
- Evaluate the magnitude of teaching of hepatocellular carcinoma (HCC) diagnostic guidelines after applying "Teaching the Teachers" concept.
II. Assess the effect of "Teaching the Teachers" concept on application of guidelines in clinical practice.
OUTLINE:
Participants complete surveys immediately after completion of a HCC diagnostic guideline webinar, monthly thereafter, and again at 6 months.
- Conditions
- Hepatocellular Carcinoma
- Being tested
- Survey Administration
- Medical subject headings
- Carcinoma, Hepatocellular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Survey AdministrationOther
Complete surveys
| Study group | Role | What they receive |
|---|---|---|
| Observational (surveys) | Participants complete surveys immediately after completion of a HCC diagnostic guideline webinar, monthly thereafter, and again at 6 months. Receives: Other: Survey Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Teaching rates of the hepatocellular carcinoma diagnosis guidelines
Paired comparisons will be performed on the proportion of learners using the practice guidelines. Will perform a multivariate analysis to assess the effect of demographic characteristics (e.g., number of years of experience, type of practice) on the teaching rate of the HCC diagnostic guidelines.
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2021
- Study start10 May 2019
- Primary completion2 Feb 2027 (estimated)
- Study completion2 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatocellular CarcinomaStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Khaled M Elsayes, MD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05143619
- Sponsor's protocol ID
- 2018-1157
- Other IDs
- NCI-2021-10961, 2018-1157
- Status last verified
- Oct 2026
- First submitted
- 18 Nov 2021
- Last updated
- 6 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines
- ClinicalTrials.gov ID
- NCT05143619
- Acronym / sponsor ID
- 2018-1157
- Conditions
- Hepatocellular Carcinoma
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 10 May 2019 (actual)
- Primary completion
- 2 Feb 2027 (estimated)
- Study completion
- 2 Feb 2027 (estimated)
- First posted
- 3 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates a concept called 'Teaching the Teachers' and whether it is helpful in disseminating guidelines on the national and international levels. "Teaching the Teachers" involves teaching the guidelines to experts who later teach the same guidelines to other radiologists, trainees, and physicians to assume the teacher's role and disseminate the guidelines and so on.
Detailed description
PRIMARY OBJECTIVES:
- Evaluate the magnitude of teaching of hepatocellular carcinoma (HCC) diagnostic guidelines after applying "Teaching the Teachers" concept.
II. Assess the effect of "Teaching the Teachers" concept on application of guidelines in clinical practice.
OUTLINE:
Participants complete surveys immediately after completion of a HCC diagnostic guideline webinar, monthly thereafter, and again at 6 months.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational (surveys) | – | Other: Survey AdministrationParticipants complete surveys immediately after completion of a HCC diagnostic guideline webinar, monthly thereafter, and again at 6 months. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Abdominal radiologists with expertise in liver imaging working in academic, community, and governmental practices in many centers around the world.
Key inclusion criteria (7 listed)
- Physicians who finished radiology residency
- Radiologists with current or completed specialized training in abdominal imaging
- Radiologists with expertise in liver imaging with no minimum number of years of experience
- Radiologists working in academic, community, and governmental practices
- Radiologists with current practice in any country around the globe
Key exclusion criteria (4 listed)
- Physicians with no formal training in radiology
- Radiologists with no expertise in abdominal/liver imaging
- Current radiology residents
- Radiologists with no interest in education and/or teaching
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Survey AdministrationComplete surveys | Other | Observational (surveys) |
Primary outcome
Teaching rates of the hepatocellular carcinoma diagnosis guidelines
Time frame: Through study completion, an average of 1 year
Paired comparisons will be performed on the proportion of learners using the practice guidelines. Will perform a multivariate analysis to assess the effect of demographic characteristics (e.g., number of years of experience, type of practice) on the teaching rate of the HCC diagnostic guidelines.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2026.
- M.D. Anderson Cancer CenterLink provided by the sponsor.
Related trials for Hepatocellular Carcinoma
Not yet recruitingPhase 3
Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Not yet recruiting
Overcoming Immunotherapy Resistance in Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-Resectable
RecruitingPhase 2
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma, HCC
Active, not recruitingPhase 2
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma
RecruitingPhase 1/2
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Recurrent or Metastatic Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Khaled M Elsayes, MD principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hepatocellular Carcinoma, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Khaled M Elsayes, MD ((713) 794-1191, kmelsayes@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Teaching rates of the hepatocellular carcinoma diagnosis guidelines (time frame: Through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.